Eiger BioPharmaceuticals stock reflects a small-cap biotech in a transitional phase as of September 19, 2026, with investors ...
Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investment Collaboration leverages ...
On the basis of product type, the global biopharmaceuticals market has been segmented into: Monoclonal antibody dominated the market during the forecast period. The successful application of ...
Paradigm Biopharmaceuticals Limited (ASX:PAR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Paradigm Biopharmaceuticals Limited ...
Asianet Newsable on MSN
BHVN stock on track for best day in over 2 months after SK Biopharmaceuticals licenses epilepsy drug: Retail now awaits obesity trial readout
Under the agreement, SK Biopharmaceuticals gets exclusive worldwide rights to Biohaven’s Kv7 platform and its lead once-daily pill, opakalim.
Paradigm Biopharmaceuticals ( ) has provided an announcement. Paradigm Biopharmaceuticals has applied for quotation on the ASX of 600,000 new ordinary fully paid shares, following ...
GYEONGGI, Korea, and ROME, March 11, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and oncology, ...
A recent US Pharmacopeia (USP) "Stimuli to the Revision Process" article emphasizes the importance of orthogonal approaches such as Flow Imaging Microscopy (FIM) to distinguish silicone oil droplets ...
SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells ...
Biopharmaceuticals, also known as biologics, are a class of medicines produced using living systems such as microorganisms, plant or animal cells, or recombinant DNA technology. Unlike traditional ...
Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Paradigm Biopharmaceuticals ( (AU:PAR)) has provided an update. Paradigm ...
SK Biopharmaceuticals said on the 8th that it recently hired Dr. Kim Tae-ho as head of the neuroscience division (VP, Global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results